#USA #Toronto #Clinical Trials #Asset Management #Resonant Clinical Solutions

Resonant Clinical Solutions Unveils New Asset Management Programs

In an effort to address the critical needs of life sciences organizations, Resonant Clinical Solutions has announced the introduction of a comprehensive suite of asset management programs. This suite, which includes Remote Asset Management (RAM), Proactive Asset Management (PAM), and Strategic Asset Management (SAM), is designed to meet the evolving demands of biorepository management, particularly in the context of clinical trials.

Understanding the Challenge of Sample Management

Clinical trials today are becoming increasingly complex. With the rise of cutting-edge therapies, such as cell and gene treatments, and the growing number of samples collected across various sites, organizations face mounting pressure to maintain rigorous data integrity, chain of custody, and audit readiness. As these needs intensify, the burden on laboratory spaces and storage budgets has become significant, infiltrating the decision-making process concerning sample storage strategies.

CEO Christophe Berthoux emphasized the importance of only making informed decisions when it comes to managing these irreplaceable scientific assets. He stated, "Research samples represent years of investment... yet decisions about them are too often made by default rather than by design."

Overview of the Programs

Recognizing these challenges, Resonant has crafted a suite of programs to allow life sciences companies to better manage their samples.

1. Remote Asset Management (RAM)

This program is ideal for organizations that store samples within their own labs or freezers. With RAM, Resonant sends biorepository specialists to customer sites to assess samples and evaluate storage practices. Their resources seamlessly integrate operational needs, allowing companies to transfer samples to Resonant's secure biorepository when necessary. Advantages include digital cataloging, real-time inventory tracking, and compliance with Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) protocols, freeing up vital resources for research and development.

2. Proactive Asset Management (PAM)

For organizations that have completed studies but still retain scattered samples, PAM is tailored to consolidate these assets efficiently. Resonant assists in the identification of closed studies and manages communication with partner labs and CROs. This ensures the seamless transfer of samples into Resonant’s long-term biorepository, which provides storage security and validation for future audits and studies.

3. Strategic Asset Management (SAM)

Organizations contemplating adjusting their storage strategies can leverage SAM. By evaluating existing inventories and storage costs, Resonant provides a detailed breakdown of alternative risks and costs associated with relocation. This program aims to assist companies in making informed decisions about insourcing or partnering with alternative vendors, ultimately optimizing their asset management strategies.

A Tailored Approach to Client Needs

Vice President Corey Stone pointed out that the programs have been deliberately crafted to cater to the specific needs of clients. "We identify which program is the most suitable for a client's unique scenario, subsequently providing the necessary infrastructure and expertise to ensure reliable, efficient, and economically practical solutions."

This new suite of Sample Asset Management Programs is now accessible and ready for implementation by life sciences organizations. Those interested in these services can find more details at resonantclinical.com/sample-asset-management or by contacting their team directly.

Resonant is currently showcasing their offerings at the ISBER 2026 International Biospecimen Summit in Toronto, where they invite attendees to stop by their booth for additional insights.

About Resonant Clinical Solutions

Resonant Clinical Solutions is renowned as a global clinical solutions partner for life sciences, focusing on managing the clinical supply chain and sample lifecycle. With over 850 employees across the U.S., U.K., and Europe, the company excels in reducing risks and navigating complexities surrounding clinical programs. Their dedication to improving sample management culminates in over 100 million research assets currently in their portfolios, ensuring the continuity and success of clinical trials worldwide.